With Phase III NASH Endpoints In Place, Intercept May Reach Market By 2018
This article was originally published in The Pink Sheet Daily
Executive Summary
Although it is the first company to reach Phase III in non-alcoholic steatohepatitis, Intercept has a long road ahead with a 2,500-patient trial that will include a 72-week interim look that could lead to initial approval in the U.S. and EU.